# Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2015

- Company: [Kiora Pharmaceuticals Inc](/companies/kprx.md) (CIK 1372514)
- Form: 10-Q
- Filed: 2015-11-12
- Accepted by EDGAR: Nov 12, 2015, 06:09 ET
- Period: 2015-09-30
- Accession: 0001144204-15-064326
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1372514/000114420415064326/v424033_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1372514/000114420415064326/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2015-07-01 to 2015-09-30 | $407.6k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2015-01-01 to 2015-09-30 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 9 months, 2015-01-01 to 2015-09-30 | $1.9m | us-gaap:InterestExpense |
| Net income | 3 months, 2015-07-01 to 2015-09-30 | −$1.4m | us-gaap:ProfitLoss |
| Net income | 9 months, 2015-01-01 to 2015-09-30 | −$5.7m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2015-07-01 to 2015-09-30 | −$0.19 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2015-01-01 to 2015-09-30 | −$2.46 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2015-01-01 to 2015-09-30 | −$2.9m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | at 2015-09-30 | $9.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-09-30 | $10.0m | us-gaap:AssetsCurrent |
| Total assets | at 2015-09-30 | $10.1m | us-gaap:Assets |
| Current liabilities | at 2015-09-30 | $1.4m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2015-09-30 | $8.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 34,259 characters.

*The following section of this Quarterly Report on Form 10-Q entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains statements that are not statements of historical fact and are forward-looking statements within the meaning of federal securities laws. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Factors that may cause our actual results to differ materially from those in the forward-looking statements include those factors described in “Item 1A. Risk Factors” beginning on page 25 of our Annual Report. You should carefully review all of these factors, as well as the comprehensive discussion of forward-looking statements on page 1 of this Quarterly Report on Form 10-Q.*

### Overview

We are a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, our first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate that is delivered into the ocular tissues through our proprietary innovative drug delivery system, the EyeGate® II Delivery System. EGP-437 is being developed under the 505(b)(2) New Drug Application, or NDA, regulatory pathway for drugs submitted for approval to the U.S. Food and Drug Administration, or FDA, which enables an applicant to rely, in part, on the FDA’s findings of safety and efficacy for an existing product, or published literature, in support of its NDA. The EyeGate® II Delivery System and EGP-437 are designed to address two major issues in ophthalmic medicine: lack of patient compliance and safety. The EyeGate® II Delivery System features a compact, elegant, and easy-to-use device that we believe has the potential to deliver drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. The EyeGate® II Delivery System is easy-to-use, only takes a few minutes to employ and has been utilized to administer more than 1,700 experimental treatments. We hold worldwide commercialization rights to the EyeGate® II Delivery System.

As we are in our developmental stage, we have not generated any revenue. We have never been profitable and, from December 26, 2004 (inception) through September 30, 2015, our losses from operations have been $62.6 million. Our net loss was approximately $5.7 million and $1.2 million for the nine months ended September 30, 2015 and 2014, respectively. Similarly, we incurred a net loss of approximately $1.4 million for the three months ended September 30, 2015 and a net profit of approximately $0.3 million for the three months ended September 30, 2014. We expect to incur significant expenses and increasing operating losses for the foreseeable future as we continue the development and clinical trials of, and seek regulatory approval for, our EGP-437 and EyeGate® II Delivery System, or the EGP-437 Combination Product, and any other product candidates we advance to clinical development. If we obtain regulatory approval for the EGP-437 Combination Product, we expect to incur significant expenses in order to create an infrastructure to support the commercialization of the EGP-437 Combination Product, including sales, marketing and distribution functions.

On July 9, 2015, we entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International, Inc., or Valeant, through which we granted Valeant exclusive, worldwide commercial and manufacturing rights to our EyeGate® II Delivery System and EGP-437 combination product, or our Product, in the field of uveitis, as well as a right of last negotiation to license our Product for other indications. Under the agreement, Valeant paid us an upfront payment of $1.0 million. We are eligible to receive milestone payments totaling up to $32.5 million, upon and subject to the achievement of certain specified developmental and commercial milestones. In addition, we are eligible to receive royalties based on a specified percent of net sales of our Product throughout the world, subject to adjustment in certain circumstances.

We will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.

We were formed in Delaware on December 26, 2004. We were originally incorporated in 1998 under the name of Optis France S.A. in Paris, France. At that time, the name of the French corporation was changed to EyeGate Pharma S.A.S. and became a subsidiary of Eyegate Pharmaceuticals, Inc.

### Financial Overview

### Research and Development Expenses

We expense all research and development expenses as they are incurred. Research and development expenses primarily include:

- non-clinical development, preclinical research, and clinical trial and regulatory-related costs;
- expenses incurred under agreements with sites and consultants that conduct our clinical trials;
- expenses related to generating, filing, and maintaining intellectual property; and
- employee-related expenses, including salaries, benefits, travel and stock-based compensation expense.

Substantially all of our research and development expenses to date have been incurred in connection with EGP-437. We expect our research and development expenses to increase for the foreseeable future as we advance our EGP-437 Combination Product through clinical development, including the conduct of our planned clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We are unable to estimate with any certainty the costs we will incur in the continued development of our EGP-437 Combination Product. Clinical development timelines, the probability of success and development costs can differ materially from expectations.

We may never succeed in achieving marketing approval for our product candidate.

The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:

- per patient trial costs;
- the number of sites included in the trials;
- the countries in which the trials are conducted;
- the length of time required to enroll eligible patients;
- the number of patients that participate in the trials;
- the number of doses that patients receive;
- the cost of comparative agents used in trials;
- the drop-out or discontinuation rates of patients;
- potential additional safety monitoring or other studies requested by regulatory agencies;
- the duration of patient follow-up; and
- the efficacy and safety profile of the product candidate.

We do not expect our EGP-437 Combination Product to be commercially available, if at all, for the next several years.

### General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation. Our general and administrative expenses consisted primarily of payroll expenses for our full-time employees. Other general and administrative expenses include professional fees for auditing, tax, patent costs and legal services.

We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a publicly-traded company and maintaining compliance with exchange listing and SEC requirements. These increases will likely include higher consulting costs, legal fees, accounting fees, directors’ and officers’ liability insurance premiums and fees associated with investor relations.

### Total Other Income (Expense)

Total other income (expense) consists primarily of interest income we earn on interest-bearing accounts, and interest expense incurred on our outstanding debt including non-cash interest resulting from the accretion of original issue discount on certain of our outstanding notes. We also received the proceeds of certain research and development tax credits related to EyeGate Pharma S.A.S.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to our financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.

### Accrued Research and Development Expenses

As part of the process of preparing financial statements, we are required to estimate and accrue research and development expenses. This process involves the following:

- communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost;
- estimating and accruing expenses in our financial statements as of each balance sheet date based on facts and circumstances known to us at the time; and
- periodically confirming the accuracy of our estimates with selected service providers and making adjustments, if necessary.

Examples of estimated research and development expenses that we accrue include:

- fees paid to contract research organizations and investigative sites in connection with clinical studies;
- fees paid to contract manufacturing organizations in connection with non-clinical development, preclinical research, and the production of clinical study materials; and
- professional service fees for consulting and related services.

We base our expense accruals related to non-clinical development, preclinical studies, and clinical trials on our estimates of the services received and efforts expended pursuant to contracts with organizations/consultants that conduct and manage clinical studies on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts may depend on many factors, such as the successful enrollment of patients, site initiation and the completion of clinical study milestones. Our service providers invoice us as milestones are achieved and monthly in arrears for services performed. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of accrued research and development expenses after a reporting period.

However, due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies and other research activities.

### Stock-Based Compensation

We have issued options to purchase our common stock. We account for stock based compensation in accordance with ASC 718, *Compensation - Stock Compensation*. ASC 718 establishes accounting for stock-based awards exchanged for employee services. Under the fair value recognition provisions of ASC 718, share based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service/vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based payment awards require the use of highly subjective assumptions, including the expected life of the stock-based payment awards and stock price volatility.

We estimate the grant date fair value of stock options and the related compensation expense, using the Black-Scholes option valuation model. This option valuation model requires the input of subjective assumptions including: (1) expected life (estimated period of time outstanding) of the options granted, (2) volatility, (3) risk-free rate and (4) dividends. Because share-based compensation expense is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. We have estimated expected forfeitures of stock options based on our historical turnover rate and used these rates in developing a future forfeiture rate. If our actual forfeiture rate varies from our estimates, additional adjustments to compensation expense may be required in future periods. In general, the assumptions used in calculating the fair value of stock-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future.

### Significant Factors Used in Determining the Fair Value of Our Common Stock

Prior to the IPO, the fair value of the shares of common stock that underlie the stock options we have granted under the plan has historically been determined by our board of directors based upon information available to it at the time of grant. Prior to December 31, 2011, our board of directors did not conduct any formal valuation procedure or commission any third party valuation or appraisal in connection with its determinations of the fair value of its common stock. Our board of directors considered the most persuasive evidence of fair value to be the prices at which our securities were sold in actual arms’ length transactions. Our board of directors also considered numerous objective and subjective factors in the assessment of fair value, including reviews of our business and financial condition, the conditions of the industry in which we operate and the markets that we serve and general economic, market and United States and global capital market conditions, an analysis of publicly traded peer companies, the lack of marketability of our common stock, the likelihood of achieving a liquidity event for the shares of common stock underlying the stock options in question, such as an initial public offering or sale, the preferences and privileges of the preferred stock and common stock, the status of strategic initiatives being undertaken by our management and board of directors and, after December 31, 2011, independent third party valuations of our common stock. All options have been granted at exercise prices not less than the fair value of the underlying shares on the date of grant.

During nine months ended September 30, 2015, we granted options to purchase 535,393 shares of our common stock.

### Other Information

### JOBS Act

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1 billion or more, (b) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering, (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

### Temporary Equity and Non-Controlling Interest

Prior to the IPO, certain of our convertible preferred stock issuances were sold jointly with shares of EyeGate Pharma S.A.S., (which were convertible into shares of our corresponding convertible preferred stock upon certain circumstances) resulting in a non-controlling interest. Such non-controlling interest and the related convertible preferred stock are classified as temporary equity on our condensed consolidated balance sheet, and we record the interest in the earnings or loss of the subsidiary not attributable to us as net income (loss) attributable to non-controlling interests in the condensed consolidated statements of operations and comprehensive loss. In connection with the IPO, both the convertible preferred stock and the shares of our subsidiary not held by us were converted into shares of our Common Stock.

### Results of Operations

### Comparison of Three Months ended September 30, 2015 and 2014

The following table summarizes the results of our operations for the three months ended September 30, 2015 and 2014:

| Operating expenses: | Three Months Ended September 30, 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Research and development | $407,571 | $111,600 | $295,971 |
| General and administrative | 946,180 | 480,450 | 465,730 |
| Total operating expenses | 1,353,751 | 592,050 | 761,701 |
| Other (expense) income, net: | (1,785) | 942,308 | (944,093) |
| Net (loss) income | (1,355,536) | 350,258 | (1,705,794) |
| Net income attributable to non-controlling interest | - | (40,666) | 40,666 |
| Deemed dividend on preferred stock | - | - | - |
| Net loss to Eyegate Pharmaceuticals, Inc. | $(1,355,536) | $309,592 | $(1,665,128) |

*Research and Development Expenses.* Research and development expenses were $0.408 million for the three months ended September 30, 2015 compared to $0.112 million for the three months ended September 30, 2014. The increase of $0.296 million is primarily due to an increase in clinical activity related to the resumption of our Phase III clinical trial for the treatment of anterior uveitis and Phase I/II clinical trial for the treatment of macular edema.

*General and Administrative Expenses.* General and administrative expenses were $0.946 million for the three months ended September 30, 2015 compared to $0.480 million for the three months ended September 30, 2014. The increase of $0.466 million was due primarily to an increase in stock compensation changes for options issued in connection with our IPO in February 2015 and our secondary stock offering in August 2015. Increases in payroll and other expenses were also realized as company operations have expanded following the receipt of funds from our two recent equity financings.

*Other Income (Expense).* Total other income (expense) was ($0.002) million and $0.942 million for the three months ended September 30, 2015 and 2014, respectively. The 2015 activity is interest income earned offset by some minor currency exchange adjustments while the 2014 activity was comprised primarily of $0.882 million from warrant liability adjustments and extinguishment of research liability of $240,000.

### Comparison of Nine Months ended September 30, 2015 and 2014

The following table summarizes the results of our operations for the nine months ended September 30, 2015 and 2014:

| Operating expenses: | Nine Months Ended September 30, 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Research and development | $1,333,118 | $421,903 | $911,215 |
| General and administrative | 2,668,513 | 1,646,910 | 1,021,603 |
| Total operating expenses | 4,001,631 | 2,068,813 | 1,932,818 |
| Other income (expense), net: | (1,696,344) | 869,245 | (2,565,589) |
| Net loss | (5,697,975) | (1,199,568) | (4,498,407) |
| Net income attributable to non-controlling interest | (5,177) | (157,928) | 152,751 |
| Deemed dividend on preferred stock | (8,222,008) | - | (8,222,008) |
| Net loss to Eyegate Pharmaceuticals, Inc | $(13,925,160) | $(1,357,496) | $(12,567,664) |

*Research and Development Expenses.* Research and development expenses were $1.333 million for the nine months ended September 30, 2015 compared to $0.422 million for the nine months ended September 30, 2014. The increase of $0.911 million is primarily due to an increase in clinical activity related to the resumption of Phase III clinical trial for the treatment of anterior uveitis and the Phase I/II macular edema trial.

*General and Administrative Expenses.* General and administrative expenses were $2.669 million for the nine months ended September 30, 2015 compared to $1.647 million for the nine months ended September 30, 2014. The increase of $1.022 million was due primarily to an increase in stock compensation changes for options issued in connection with the Company’s February IPO and August’s secondary stock offering. Increases in payroll and other expenses were also realized as company operations have expanded following the receipt of funds from our two equity raises.

*Other (Expense) Income.* Total other (expense) income was ($1.696) million and $0.869 million for the nine months ended September 30, 2015 and 2014, respectively. The change is comprised primarily of an interest expense for 2015 that is $1.666 million greater than the 2014 expense due to a non-cash interest charge on the beneficial conversion features on the Company’s notes. Additionally the favorable change in fair value of the warrant liability of $0.223 in 2015 is less than a comparable favorable change in the 2014 warrant liability of $0.877 million and extinguishment of research liability of $240,000 for the nine months ended September 30, 2014.

### Liquidity and Capital Resources

In addition to proceeds from the two public offerings of our common stock, we have funded our operations since inception through the issuance of convertible preferred stock, shares of our subsidiary and convertible promissory notes and, to a lesser extent, through research and development tax credits. Through September 30, 2015, we had raised a total of $70.4 million from such sales of our equity securities and debt instruments.

On July 9, 2015, Eyegate received the initial $1.000 million payment from Valeant as provided under the licensing agreement executed on that date.

At September 30, 2015, we had cash and cash equivalents totaling $ 9.919 million.

The following table sets forth the primary sources and uses of cash for the nine months ended September 30, 2015 and 2014:

|  | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: |
| Cash used in operating activities | $(2,910,509) | $(514,482) |
| Cash used in investing activities | (20,000) | - |
| Cash provided by financing activities | 12,607,973 | 288,790 |

27

### Comparison of Nine Months Ended September 30, 2015 and 2014

*Operating Activities.* Net cash used in operating activities was $2.911 million for the nine months ended September 30, 2015, compared to net cash used in operating activities of $0.514 million for the nine months ended September 30, 2014. The primary use of cash was to fund operating losses of $5.698 million in 2015 off-set in part by $1.908 million of non-cash interest expense related to the beneficial conversion feature on the Company’s convertible notes. The remainder of the negative cash flows resulted from the extinguishment of operating liabilities after funds became available from the IPO proceeds.

*Financing Activities.* On February 19, 2015, we received gross proceeds of approximately $4.092 million from the IPO. Net proceeds from the initial offering were approximately $2.718 million after costs related to the offering were satisfied. On August 5, 2015, we received gross proceeds of approximately $10.002 million from a second stock offering. Net proceeds from that offering were approximately $8.748 million after costs related to the offering were satisfied.

### Funding Requirements and Other Liquidity Matters

Our EGP-437 Combination Product is still in clinical development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

- seek marketing approval for our EGP-437 Combination Product;
- establish a sales and marketing infrastructure to commercialize our EGP-437 Combination Product in the United States, if approved;
- add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts.

On August 5, 2015, we closed an underwritten public offering of 1,176,470 shares of our common stock and warrants to purchase 1,176,470 shares of our common stock at a combined public offering price of $8.50 per share of common stock and warrant, before underwriting discounts and commissions. The warrants have an exercise price of $10.62 per share, are immediately exercisable, and expire on August 5, 2020. At the closing of the offering, we also issued and sold additional warrants to purchase up to 176,470 shares of our common stock in connection with the full exercise of the underwriters’ over-allotment option to purchase additional warrants. The underwriters’ had 45 days following the closing of the offering to exercise an over-allotment option to purchase an additional 176,470 shares of our common stock. The over-allotment option to purchase such shares was not exercised and has since terminated. The net proceeds to us were approximately $8.8 million, assuming no exercise of the warrants, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Because of the numerous risks and uncertainties associated with the development and commercialization of our EGP-437 Combination Product, if approved, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our EGP-437 Combination Product.

Our future capital requirements will depend on many factors, including:

- the costs, timing and outcome of regulatory review;
- the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for our EGP-437 Combination Product, if approved;
- the revenue, if any, received from commercial sales of our EGP-437 Combination Product, if approved; and
- the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, including our EGP-437 Combination Product, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market EGP-437 that we would otherwise prefer to develop and market ourselves.

Including the proceeds from the August 5, 2015 closing of our secondary stock offering, we will have sufficient cash to fund planned operations for approximately 15 to 18 months, however, the acceleration or reduction of cash outflows by management can significantly impact the timing for raising additional capital to complete development of its products. To continue development, we will need to raise additional capital through debt and/or equity financing, or access additional funding through grants. Although we completed the IPO and secondary offering, additional capital may not be available on terms favorable to EyeGate, if at all. Accordingly, no assurances can be given that management will be successful in these endeavors. These conditions raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should we be unable to continue as a going concern.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements as or September 30, 2015.

### Contractual Obligations

The following table summarizes our contractual obligations as of September 30, 2015:

|  | Total | Less than 1 year | 1-3 years | 3-5 years |
| --- | ---: | ---: | ---: | ---: |
| Operating Leases (1) | $222,922 | $15,186 | $207,736 | $- |
| Licensing Agreement (2) | 75,000 | 12,500 | 25,000 | 37,500 |
| Purchase Obligations (3) | 3,135,000 | 1,600,000 | 1,535,000 | - |
| Total (4) | $3,432,922 | $1,627,686 | $1,767,736 | $37,500 |

(1) Operating lease obligations reflect our obligation to make payments in connection with leases for our office space.

(2) Purchase obligations represent our commitments under purchase orders, including those made under our License agreement with the University Of Miami School Of Medicine.

(3) The Company entered into a Master Service Agreement with a CRO. The CRO will provide clinical research services for Phase III study in patients with non-infectious anterior segment uveitis.

(4) This table does not include (a) anticipated expenditures under supply agreements for periods for which we are not yet bound under binding purchase orders, (b) contracts that are entered into in the ordinary course of business that are not material in the aggregate in any period presented above.

In addition, in the course of normal business operations, we have agreements with contract service providers to assist in the performance of our research and development and manufacturing activities. Expenditures to CROs vary based on the study and phases during the clinical development stages. Subject to required notice periods and our obligations under binding purchase orders, we can elect to discontinue the work under these agreements at any time. We could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and even long-term commitments of cash.

## Controls and procedures

As filed, 3,213 characters.

### Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the President and Chief Executive Officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of this Quarterly Report on the Form 10-Q, our management, under the supervision and with the participation of our President and Chief Executive Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2015. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and our management necessarily was required to apply its judgment in evaluating and implementing our disclosure controls and procedures. Based upon the evaluation described above, our President and Chief Executive Officer has concluded that he believes that our disclosure controls and procedures have the following material weaknesses existing as of the end of the period covered by this report, in providing reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our President and Chief Executive Officer, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms:

- Lack of experienced accounting and financial reporting personnel to manage the complexities of SEC financial reporting which resulted in significant changes to the financial statements as a result of our audit.
- Due to the limited number of people working in the office, many critical duties are combined and given to the available employees. Presently, a single individual prepares and signs checks, reconciles bank accounts, performs all payroll duties, and maintains the general ledger.
- Lack of adequate disclosure controls resulted in large audit adjustments related to a material contract.

If we are unable to correct deficiencies in internal controls in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC may be adversely affected.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,270 characters.

In addition to the risk factors below, Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 31, 2015, contains risk factors identified by the Company. Except for the risk factors below, there have been no material changes to the risk factors we previously disclosed. Our operations could also be affected by additional factors that are not presently known to us or by factors that we currently consider immaterial to our business.

*Disputes may arise under our Valeant License Agreement, including disputes related to the scope of rights granted thereunder.*

Disputes may arise under our license agreement with Valeant Pharmaceuticals Luxembourg S.à.r.l dated July 9, 2015, or Valeant License Agreement, including disputes related to the scope of rights granted thereunder. Any such disputes could lead to delays in the development or commercialization of our EGP-437 Combination Product and could result in time-consuming and expensive litigation or arbitration, which may not be resolved in our favor. Either party may terminate the Valeant License Agreement in its entirety if the other party materially breaches the Valeant License Agreement and the breach remains uncured for a defined cure period, and either party may terminate the Valeant License Agreement in its entirety upon the bankruptcy of the other party. We may terminate the Valeant License Agreement following commercial launch of our EGP 437-Combination Product if Valeant ceases selling and distributing our EGP 437-Combination Product in the United States for a defined period of time, subject to certain limitations. Valeant may terminate the Valeant License Agreement at any time, on a without cause basis, by providing 90 days written notice, or immediately upon the determination by a court of competent jurisdiction if Valeant’s actions pursuant to the terms of the Valeant License Agreement infringe upon the intellectual property rights of a third party. We cannot make assurances that this agreement will not be terminated in accordance with these terms, and such termination could have a material adverse impact on our future business, results of operations, financial conditions, and the trading price of our common stock.

Filed Nov 12, 2015.
Source: SEC EDGAR, the filing index for accession 0001144204-15-064326. Last ingested by Listed: Nov 12, 2026, 17:43 ET. No prices; not investment advice.
